FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2576993281> ?p ?o ?g. }

• W2576993281 endingPage "1952" @default.
• W2576993281 startingPage "1944" @default.
• W2576993281 abstract "Therapy with nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with enteropathy in humans and experimental animals, a cause of considerable morbidity. Unlike foregut NSAID-associated mucosal lesions, most treatments for this condition are of little efficacy. We propose that the endogenously released intestinotrophic hormone glucagon-like peptide-2 (GLP-2) prevents the development of NSAID-induced enteropathy. Since the short-chain fatty acid receptor FFA3 is expressed on enteroendocrine L cells and on enteric nerves in the gastrointestinal tract, we further hypothesized that activation of FFA3 on L cells protects the mucosa from injury via GLP-2 release with enhanced duodenal HCO3 − secretion. We thus investigated the effects of synthetic selective FFA3 agonists with consequent GLP-2 release on NSAID-induced enteropathy. We measured duodenal HCO3 − secretion in isoflurane-anesthetized rats in a duodenal loop perfused with the selective FFA3 agonists MQC or AR420626 (AR) while measuring released GLP-2 in the portal vein (PV). Intestinal injury was produced by indomethacin (IND, 10 mg/kg, sc) with or without MQC (1–10 mg/kg, ig) or AR (0.01–0.1 mg/kg, ig or ip) treatment. Luminal perfusion with MQC or AR (0.1–10 µM) dose-dependently augmented duodenal HCO3 − secretion accompanied by increased GLP-2 concentrations in the PV. The effect of FFA3 agonists was inhibited by co-perfusion of the selective FFA3 antagonist CF3-MQC (30 µM). AR-induced augmented HCO3 − secretion was reduced by iv injection of the GLP-2 receptor antagonist GLP-2(3-33) (3 nmol/kg), or by pretreatment with the cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor CFTRinh-172 (1 mg/kg, ip). IND-induced small intestinal ulcers were dose-dependently inhibited by intragastric administration of MQC or AR. GLP-2(3-33) (1 mg/kg, ip) or CF3-MQC (1 mg/kg, ig) reversed AR-associated reduction in IND-induced enteropathy. In contrast, ip injection of AR had no effect on enteropathy. These results suggest that luminal FFA3 activation enhances mucosal defenses and prevents NSAID-induced enteropathy via the GLP-2 pathway. The selective FFA3 agonist may be a potential therapeutic candidate for NSAID-induced enteropathy." @default.
• W2576993281 created "2017-01-26" @default.
• W2576993281 creator A5015086368 @default.
• W2576993281 creator A5026006895 @default.
• W2576993281 creator A5044581797 @default.
• W2576993281 creator A5049513846 @default.
• W2576993281 creator A5050459530 @default.
• W2576993281 creator A5055852624 @default.
• W2576993281 creator A5073646578 @default.
• W2576993281 creator A5083708850 @default.
• W2576993281 date "2017-05-18" @default.
• W2576993281 modified "2023-10-04" @default.
• W2576993281 title "FFA3 Activation Stimulates Duodenal Bicarbonate Secretion and Prevents NSAID-Induced Enteropathy via the GLP-2 Pathway in Rats" @default.
• W2576993281 cites W1520620836 @default.
• W2576993281 cites W1545629156 @default.
• W2576993281 cites W1586629783 @default.
• W2576993281 cites W1808736595 @default.
• W2576993281 cites W1954119987 @default.
• W2576993281 cites W1967893045 @default.
• W2576993281 cites W1974667501 @default.
• W2576993281 cites W1977235966 @default.
• W2576993281 cites W1995636631 @default.
• W2576993281 cites W1998857192 @default.
• W2576993281 cites W1999059100 @default.
• W2576993281 cites W2002924275 @default.
• W2576993281 cites W2007410107 @default.
• W2576993281 cites W2014697995 @default.
• W2576993281 cites W2016964093 @default.
• W2576993281 cites W2027576421 @default.
• W2576993281 cites W2035421462 @default.
• W2576993281 cites W2054781816 @default.
• W2576993281 cites W2057626906 @default.
• W2576993281 cites W2061693202 @default.
• W2576993281 cites W2063493835 @default.
• W2576993281 cites W2066410861 @default.
• W2576993281 cites W2068338895 @default.
• W2576993281 cites W2069247721 @default.
• W2576993281 cites W2090933934 @default.
• W2576993281 cites W2099663899 @default.
• W2576993281 cites W2102796878 @default.
• W2576993281 cites W2107510055 @default.
• W2576993281 cites W2122447338 @default.
• W2576993281 cites W2124272026 @default.
• W2576993281 cites W2135339549 @default.
• W2576993281 cites W2140663833 @default.
• W2576993281 cites W2145479438 @default.
• W2576993281 cites W2153567889 @default.
• W2576993281 cites W2161854425 @default.
• W2576993281 cites W2170774855 @default.
• W2576993281 cites W2252868309 @default.
• W2576993281 cites W2302380741 @default.
• W2576993281 cites W2336050226 @default.
• W2576993281 cites W2419516382 @default.
• W2576993281 cites W2036795871 @default.
• W2576993281 doi "https://doi.org/10.1007/s10620-017-4600-4" @default.
• W2576993281 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5511769" @default.
• W2576993281 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28523577" @default.
• W2576993281 hasPublicationYear "2017" @default.
• W2576993281 type Work @default.
• W2576993281 sameAs 2576993281 @default.
• W2576993281 citedByCount "15" @default.
• W2576993281 countsByYear W25769932812017 @default.
• W2576993281 countsByYear W25769932812018 @default.
• W2576993281 countsByYear W25769932812019 @default.
• W2576993281 countsByYear W25769932812020 @default.
• W2576993281 countsByYear W25769932812021 @default.
• W2576993281 countsByYear W25769932812022 @default.
• W2576993281 countsByYear W25769932812023 @default.
• W2576993281 crossrefType "journal-article" @default.
• W2576993281 hasAuthorship W2576993281A5015086368 @default.
• W2576993281 hasAuthorship W2576993281A5026006895 @default.
• W2576993281 hasAuthorship W2576993281A5044581797 @default.
• W2576993281 hasAuthorship W2576993281A5049513846 @default.
• W2576993281 hasAuthorship W2576993281A5050459530 @default.
• W2576993281 hasAuthorship W2576993281A5055852624 @default.
• W2576993281 hasAuthorship W2576993281A5073646578 @default.
• W2576993281 hasAuthorship W2576993281A5083708850 @default.
• W2576993281 hasBestOaLocation W25769932812 @default.
• W2576993281 hasConcept C103395026 @default.
• W2576993281 hasConcept C105702510 @default.
• W2576993281 hasConcept C126322002 @default.
• W2576993281 hasConcept C134018914 @default.
• W2576993281 hasConcept C146957229 @default.
• W2576993281 hasConcept C170774537 @default.
• W2576993281 hasConcept C185592680 @default.
• W2576993281 hasConcept C2776809568 @default.
• W2576993281 hasConcept C2778426112 @default.
• W2576993281 hasConcept C2779134260 @default.
• W2576993281 hasConcept C2779281246 @default.
• W2576993281 hasConcept C2781219945 @default.
• W2576993281 hasConcept C46699223 @default.
• W2576993281 hasConcept C49039625 @default.
• W2576993281 hasConcept C55493867 @default.
• W2576993281 hasConcept C71315377 @default.
• W2576993281 hasConcept C71924100 @default.
• W2576993281 hasConceptScore W2576993281C103395026 @default.
• W2576993281 hasConceptScore W2576993281C105702510 @default.
• W2576993281 hasConceptScore W2576993281C126322002 @default.

• next